JPRN-jRCT2080221290未知2 期
A randomized phase II trial of TSU-68 in combination with TS-1 and CDDP versus TS-1 and CDDP in patients with advanced gastric cancer
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 92
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Histologically or cytologically proven unresectable or recurrent gastric adenocarcinoma.
- •2)Target lesions confirmed by Imaging-based evaluation such as CT within 28 days before enrollment.
- •3)No prior treatment (ex. radiation therapy, chemotherapy, hormonal therapy) for gastric cancer.
- •4)Adequate oral intake.
- •5)ECOG Performance Status of 0 to 1.
排除标准
- •1)Contraindication to TS-1 or CDDP.
- •2)Severe complications.
- •3)Colon disorder with active inflammation.
- •4)History of severe thrombosis or embolism.
- •5)Active double cancer.
研究者
相似试验
未知
2 期
An early phase II study of TSU-68 in combination with docetaxel in patients with advanced and metastatic breast cancer progressing anthracycline containing regimen.Breast cancerJPRN-jRCT2080221143Taiho Pharmaceutical Co., Ltd.19
未知
1 期
A Phase I study of TSU-68 in combination with S-1 in patients with advanced hepatocellular carcinoma who are not candidates for conventional therapyHepatocellular carcinomaJPRN-jRCT2080221925Taiho Pharmaceutical Co., Ltd.18
进行中（未招募）
1 期
Trastuzumab deruxtecan for subjects with HER2-mutated metastatic NSCLCHER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864EUCTR2020-003427-42-FRDaiichi Sankyo, Inc.150
进行中（未招募）
1 期
Trastuzumab deruxtecan for subjects with HER2-mutated metastatic NSCLCHER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: LLTClassification code 10064049Term: Lung adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2020-003427-42-ITDAIICHI SANKYO INC.150
进行中（未招募）
2 期
Trastuzumab deruxtecan for subjects with HER2-mutated metastatic NSCLCon-Small Cell Lung CancerJPRN-jRCT2061200038Inoguchi Akihiro150